Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Crit Rev Oncol Hematol ; 157: 103144, 2021 Jan.
Article in English | MEDLINE | ID: mdl-33254035

ABSTRACT

Management of stage III non- small cell lung cancer (NSCLC) is very challenging due to being a group of widely heterogeneous diseases that require multidisciplinary approaches with timely and coordinated care. The standards of care had significant changes over the last couple of years because of the introduction of consolidation therapy with checkpoint inhibitor following concurrent chemo-radiotherapy and the evolving new role of tyrosine kinase inhibitors in the adjuvant setting. The manuscript presents evidence-based recommendations for the workup, staging, treatment and follow up of the various subtypes of stage III NSCLC. The guidelines were developed by experts in various fields of thoracic oncology and guidelines development. The guidelines consider the sequence of interventions and the role of each discipline in the management of the disease taking into account the recent development and included required resources to help physicians provide better care.


Subject(s)
Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Carcinoma, Non-Small-Cell Lung/diagnosis , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/therapy , Humans , Lung Neoplasms/diagnosis , Lung Neoplasms/pathology , Lung Neoplasms/therapy , Neoplasm Staging
2.
Heart Views ; 20(3): 77-82, 2019.
Article in English | MEDLINE | ID: mdl-31620251

ABSTRACT

OBJECTIVES: The purpose of this study is to assess the diagnostic performance of coronary artery calcium score (CACS), computed tomography coronary angiography (CTCA), and the prevalence of coronary artery disease (CAD) as etiology of heart failure (HF) in the Middle Eastern population. BACKGROUND: CTCA has several advantages compared to invasive coronary angiography (ICA). However, studies on the diagnostic accuracy of CTCA and CACS in detecting the prevalence of CAD in patients with newly diagnosed HF are lacking in the Middle East. METHODS: This study included 204 patients with symptoms of HF and ejection fraction (EF) of <50% by echocardiography who underwent CTCA for diagnosis of CAD within 3 months. The exclusion criteria were defined as patients with a history of CAD, percutaneous coronary intervention, or coronary artery bypass grafting. All patients with obstructive CAD based on CTCA were referred for ICA. In addition, 30 patients with normal CTCA also underwent ICA for verification. RESULTS: The mean age was 48 ± 13 years, 69% (n = 141) were male and 31% (n = 73) were female, mean left ventricular EF was 31% ± 9%, and mean CACS was 58 ± 120. Based on the CTCA results, 169 patients had normal or nonobstructive CAD, whereas 35 patients had obstructive CAD. ICA was performed in all 35 patients with obstructive CAD; 30 of them were confirmed as having abnormal ICA, and only 5 had nonobstructive CAD. In addition, 30 patients with normal CTCA underwent ICA testing and were confirmed as having normal ICA. The CTCA had 100% sensitivity, 84% specificity, 86% positive predictive value, and 100% negative predictive value. Of the total population, 30 (15%) who were documented as having obstructive CAD were classified as CAD HF based on ICA. The remaining 174 (85%) patients were classified as having no CAD HF based on normal CTCA and/or ICA. The prevalence of CAD HF based on ICA was 15%. There was a strong correlation between CACS and both CTCA and ICA, with P = 0.001 and 0.0048, respectively. CONCLUSION: In patients with newly diagnosed HF, CACS and CTCA had a 100% sensitivity and negative value as well as overall excellent diagnostic accuracy. CACS = 0 excluded CAD as the etiology of HF with correlation between CACS groups and both CTCA and ICA. The prevalence of CAD as etiology of HF in the study population was 15%.

3.
Cancer Manag Res ; 11: 9665-9674, 2019.
Article in English | MEDLINE | ID: mdl-32009819

ABSTRACT

BACKGROUND: Cancer incidence in Saudi Arabia has increased for the last two decades, ratcheting up to global levels. The study aimed to analyze cancer trends and the contributions of various cancer types, forecast incidence, and estimate the economic burden in 2030. METHODS: A national-level cohort study utilizing the Data of Cancer Registry of patients who were diagnosed in 1999-2015. New cases in 2016-2030 were forecast and predicted based on 1999-2015 data. We used growth assumption and regression analysis to predict the trends of cancer cases. We assessed the contributions of cancer types to incidence trends. We carried forecasting of new cases and extrapolation of the potential economic burden. We conducted a sensitivity analysis of the cost of cancer with respect to changes in economic and epidemiologic factors. RESULTS: The findings suggest that the number of known cancer cases increased by 136% from 1999 to 2015 and is projected to rise by 63% in 2030. The forecast indicates female cases will account for higher number of cases and greater proportion increase. The future cost of all cancer types would be estimated at $7.91 billion in 2015 value, of which $3.76 billion will be attributable to care management and $4.15 billion in lost productivity. With the assumption of growth of the aged-standardized incidence rate, the costs of care management and lost productivity are projected to be $5.85 and $6.47 billion, respectively in 2030, an increase of 56% in each component. The future undiscounted total estimated economic burden for the period 2015-2030 would be $159.44 billion, of which 47.5% will be attributable to care management. Estimates were robust to uncertainty, but the 5-year prevalence of cancer survivorship would account for the greatest variability. CONCLUSION: Our model showed an upsurge of cancer burden in terms of incidence and the potential economic burden, which may inform cancer control measures.

4.
Ann Thorac Med ; 13(4): 198-204, 2018.
Article in English | MEDLINE | ID: mdl-30416590

ABSTRACT

BACKGROUND: While lung cancer is the leading cancer cause of death, it is largely preventable. Furthermore, early diagnosis enhances the chance of cure. Therefore, we developed guidelines for lung cancer prevention and early detection. METHODS: A multidisciplinary team of experts in lung cancer representing different health-care sectors was assembled based on the National Cancer Center request and in coordination with the Saudi Lung Cancer Association of Saudi Thoracic Society. The team reviewed various reliable international guidelines and the data and experience in the Kingdom and formulated guidelines that address the primary and secondary prevention approaches in lung cancer, including tobacco control, early diagnosis, and lung cancer screening. RESULTS: The team developed guidelines to assist healthcare professionals in the Kingdom manage the different aspects of lung cancer prevention. Primary prevention through tobacco control: the recommendations encourage all healthcare professionals in all practice settings to screen their patients for smoking and to provide counseling and if needed referral to smoking cessation programs for current smokers. For early diagnosis of patients with symptoms suspicions of lung cancer, it is expected standard of care to investigate, work up, and refer the patients appropriately. Mass screening of patients at high risk for developing lung cancer: the recommendations listed the program requirements, eligible patients, and algorithm to manage findings. However, the team does not recommend that national screening program be mandated or implemented for lung cancer at this stage until more data and studies provide stronger evidence to justify adopting a national program. CONCLUSIONS: Physicians can play an important role in preventing lung cancer by tobacco control and also detect lung cancer at earlier presentation. However, national mass screening programs require further study.

5.
Case Rep Radiol ; 2016: 2092084, 2016.
Article in English | MEDLINE | ID: mdl-27034877

ABSTRACT

This is a case report of an extremely rare cause of superior vena cava syndrome with systemic-to-pulmonary venous shunts, illustrated using different imaging modalities with successful SVC and IVC dilatation and stenting.

SELECTION OF CITATIONS
SEARCH DETAIL